Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 5/20 | 0.81 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.81 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.81 |
| ▸ | TSHR | P16473 | 3/20 | 0.81 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.81 |
| ▸ | PTGFR | P43088 | 2/20 | 0.81 |
| ▸ | HPGD | P15428 | 2/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.81 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | PGR | P06401 | 1/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.81 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23353173 | 0.91 | PTGIR (0.98) | PTGIRPTGER4PTGER2TSHRPTGER3 | |
| SCHEMBL23352857 | 0.91 | PTGIR (0.98) | PTGIRPTGER4PTGER2TSHRPTGER3 | |
| Dinoprostone SCHEMBL24223591 | 0.90 | PTGIR (1.00) | PTGIRPTGER4PTGER2TSHRPTGER3 | |
| Dinoprostone SCHEMBL23352988 | 0.90 | PTGIR (1.00) | PTGIRPTGER4PTGER2TSHRPTGER3 | |
| Dinoprostone SCHEMBL23352614 | 0.90 | PTGIR (1.00) | PTGIRPTGER4PTGER2TSHRPTGER3 | |
| Dinoprostone SCHEMBL23352819 | 0.90 | PTGIR (1.00) | PTGIRPTGER4PTGER2TSHRPTGER3 | |
| Dinoprostone SCHEMBL23352922 | 0.90 | PTGIR (1.00) | PTGIRPTGER4PTGER2TSHRPTGER3 | |
| Dinoprostone SCHEMBL24340817 | 0.90 | PTGIR (1.00) | PTGIRPTGER4PTGER2TSHRPTGER3 | |
| Dinoprostone SCHEMBL23353214 | 0.90 | PTGIR (1.00) | PTGIRPTGER4PTGER2TSHRPTGER3 | |
| Dinoprostone SCHEMBL23352791 | 0.90 | PTGIR (1.00) | PTGIRPTGER4PTGER2TSHRPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230160914-A1 | Method for Detecting Atopic Dermatitis | THE UNIVERSITY OF TOKYO (JP) | 2023-05-25 | — | — | US | claimed |
| EP-2077826-B1 | METHOD TO ENHANCE TISSUE REGENERATION | CHILDRENS MEDICAL CENTER (US) | 2013-09-04 | — | — | EP | claimed |
| EP-1140108-B1 | METHOD AND COMPOSITION FOR TREATMENT OF FEMALE SEXUAL DYSFUNCTION | SYNPHORA AB (SE) | 2004-06-23 | — | — | EP | claimed |
| EP-1140108-A1 | METHOD AND COMPOSITION FOR TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Synphora AB (SE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040248-A1 | METHOD AND COMPOSITION FOR TREATMENT OF FEMALE SEXUAL DYSFUNCTION | SYNPHORA AB (SE) | 2000-07-13 | — | — | WO | claimed |
| EP-4687496-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2026-02-11 | — | — | EP | disclosed |
| US-12534439-B2 | Xanthohumol derivatives and methods for making and using | OREGON STATE UNIVERSITY (US) | 2026-01-27 | — | — | US | disclosed |
| WO-2024200855-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO Y POLITECNICO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2024-10-03 | — | — | WO | disclosed |
| EP-4437858-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2024-10-02 | — | — | EP | disclosed |
| US-20240229070-A1 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | GENETIX BIOTHERAPEUTICS INC. | 2024-07-11 | — | — | US | disclosed |
| CN-112481211-B | Cells with increased immunomodulation and methods of use and production thereof | 儿童医院公司 | 2024-07-05 | — | — | CN | disclosed |
| US-12005039-B2 | Methods and compositions relating to lipokines for treating metabolic disorders | JOSLIN DIABETES CENTER, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-8470882-B2 | — | — | 2013-06-25 | — | — | US | disclosed |
| US-20120059061-A1 | NOVEL ANTI-INFLAMMATORY COMPOUNDS | THE UNIVERSITY OF TOKYO (JP) | 2012-03-08 | — | — | US | disclosed |
| EP-2415748-A1 | NOVEL ANTI-INFLAMMATORY COMPOUNDS | The University of Tokyo (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100105771-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105775-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. | 2010-04-29 | — | — | US | disclosed |
| EP-1140108-B1 | METHOD AND COMPOSITION FOR TREATMENT OF FEMALE SEXUAL DYSFUNCTION | SYNPHORA AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| EP-1140108-A1 | METHOD AND COMPOSITION FOR TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Synphora AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040248-A1 | METHOD AND COMPOSITION FOR TREATMENT OF FEMALE SEXUAL DYSFUNCTION | SYNPHORA AB (SE) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534439-B2 | Xanthohumol derivatives and methods for making and using | MT-CO1, MT-CO2, PC | PTGIR 2918/4885PTGER4 3387/4885PTGER2 2148/4885 |
| US-20120059061-A1 | NOVEL ANTI-INFLAMMATORY COMPOUNDS | ALOX15, ALOX15B, ALOX12 | PTGIR 39/4885PTGER4 30/4885PTGER2 52/4885 |
| US-20100105771-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | PTGIS, PTGES, PTGIR | PTGIR 3/4885PTGER4 17/4885PTGER2 14/4885 |
| US-20100105775-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | PTGIS, PTGES, PTGIR | PTGIR 3/4885PTGER4 17/4885PTGER2 14/4885 |
| US-12005039-B2 | Methods and compositions relating to lipokines for treating metabolic disorders | CPT1B, LIPE, LIPC | PTGIR 1554/4885PTGER4 2306/4885PTGER2 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.